AI assistant
Vivesto — Board/Management Information 2014
Jan 21, 2014
3124_rns_2014-01-21_0a12d6ce-6336-469a-b23f-f9168de14a4f.pdf
Board/Management Information
Open in viewerOpens in your device viewer
PRESS RELEASE
Oasmia€s Chief Financial Officer Weine Nejdemo retires
Oasmia€s Chief Financial Officer Weine Nejdemo has decided toretire. Weine, who turns 66 this year, will stay with the company until April 17.
The recruitment process for a replacement has been initiated.
About Oasmia Pharmaceutical AB
Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company€sproduct development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics which, in comparison with current alternatives, show improved properties, reduced side-effects, and expanded applications. The company€s product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365).
For more information, please contact: Mikael Widell, Vice President Communications, Oasmia Pharmaceutical AB. E-mail: [email protected] Phone: +46 (0) 18 50 54 40. Information is also available at twitter.com/oasmia
€Oasmia is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 13.10, CET on January 21, 2014.•
2014-01-21